Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $592.26 million. The enterprise value is $531.33 million.
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 683.93 million shares outstanding. The number of shares has increased by 2.18% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 683.93M |
| Shares Change (YoY) | +2.18% |
| Shares Change (QoQ) | +43.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 649.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.99 |
| Forward PS | 1.79 |
| PB Ratio | 2.68 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.79 |
| EV / EBITDA | 164.86 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.77, with a Debt / Equity ratio of 0.51.
| Current Ratio | 3.77 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 17.02 |
| Debt / FCF | n/a |
| Interest Coverage | -0.41 |
Financial Efficiency
Return on equity (ROE) is -5.38% and return on invested capital (ROIC) is -0.62%.
| Return on Equity (ROE) | -5.38% |
| Return on Assets (ROA) | -0.52% |
| Return on Invested Capital (ROIC) | -0.62% |
| Return on Capital Employed (ROCE) | -1.10% |
| Revenue Per Employee | $735,644 |
| Profits Per Employee | -$29,309 |
| Employee Count | 404 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 0.63 |
Taxes
In the past 12 months, Pharming Group has paid $3.35 million in taxes.
| Income Tax | 3.35M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.54% in the last 52 weeks. The beta is 0.44, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -10.54% |
| 50-Day Moving Average | 8.50 |
| 200-Day Moving Average | 8.45 |
| Relative Strength Index (RSI) | 52.62 |
| Average Volume (20 Days) | 2,824 |
Short Selling Information
| Short Interest | 1,582 |
| Short Previous Month | 2,533 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, Pharming Group had revenue of $297.20 million and -$11.84 million in losses. Loss per share was -$0.02.
| Revenue | 297.20M |
| Gross Profit | 261.80M |
| Operating Income | -3.59M |
| Pretax Income | -15.41M |
| Net Income | -11.84M |
| EBITDA | 3.22M |
| EBIT | -3.59M |
| Loss Per Share | -$0.02 |
Full Income StatementBalance Sheet
The company has $167.89 million in cash and $112.31 million in debt, giving a net cash position of $55.58 million or $0.08 per share.
| Cash & Cash Equivalents | 167.89M |
| Total Debt | 112.31M |
| Net Cash | 55.58M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 221.06M |
| Book Value Per Share | 0.32 |
| Working Capital | 204.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.80 million and capital expenditures -$790,000, giving a free cash flow of -$2.59 million.
| Operating Cash Flow | -1.80M |
| Capital Expenditures | -790,000 |
| Free Cash Flow | -2.59M |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
Gross margin is 88.09%, with operating and profit margins of -1.21% and -3.98%.
| Gross Margin | 88.09% |
| Operating Margin | -1.21% |
| Pretax Margin | -2.86% |
| Profit Margin | -3.98% |
| EBITDA Margin | 1.08% |
| EBIT Margin | -1.21% |
| FCF Margin | n/a |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.18% |
| Shareholder Yield | -2.18% |
| Earnings Yield | -2.00% |
| FCF Yield | -0.44% |
Analyst Forecast
The average price target for Pharming Group is $30.00, which is 233.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.00 |
| Price Target Difference | 233.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 8.20% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.43 |
| Piotroski F-Score | 3 |